Overview

Buprenorphine Dosing Interval - 5

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

The purpose of this study is to explore the feasibility of extending the dosing interval of well maintained buprenorphine patients to 48 and 72 hours, leading to eventual 3 times/week dosing.

Phase:

Phase 2

Details

Lead Sponsor:

National Institute on Drug Abuse (NIDA)

Treatments:

Buprenorphine